Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

630.49 +0.81 (+0.13%)

Streaming Delayed Price Updated: 10:09 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

62 63 Next >

The 3 Most Undervalued Biotech Stocks to Buy in March 2024 ↗

March 13, 2024

These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March.

Via InvestorPlace

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

March 13, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

March 12, 2024

$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture? ↗

March 01, 2024

Via Benzinga

The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts ↗

February 27, 2024

Via Benzinga

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗

February 22, 2024

Via Benzinga

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

March 11, 2024

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗

March 09, 2024

Good news could be in store for all three of these drugmakers.

Via The Motley Fool

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

March 08, 2024

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in March ↗

March 08, 2024

These stocks are worth buying in most months of the year.

Via The Motley Fool

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

March 08, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 No-Brainer Biotech Stocks to Buy Right Now ↗

February 21, 2024

These stocks are used to beating the market.

Via The Motley Fool

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading

February 20, 2024

Via Investor Brand Network

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

February 26, 2024

Via Benzinga

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

February 23, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today ↗

February 06, 2024

Via Benzinga

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

February 21, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗

February 20, 2024

The FDA put studies in eczema and asthma treatment on clinical hold.

Via Investor's Business Daily

Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling ↗

February 20, 2024

The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

2 Top Growth Stocks to Buy With $1,000 Right Now ↗

February 18, 2024

Even a modest starting investment in the right stocks could pay off in the years ahead.

Via The Motley Fool

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

February 16, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 12, 2024

Via Benzinga

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗

February 09, 2024

There's room for multiple winners in the fast-growing weight-loss market.

Via The Motley Fool

The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗

February 06, 2024

Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.

Via InvestorPlace

Topics Artificial Intelligence

Regeneron Announces Investor Conference Presentations

February 06, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast ↗

February 06, 2024

4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.